The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
Open accessAbstract
The effectiveness of anticancer agents may be hindered by low solubility in water, poor permeability, and high efflux from cells. Nanomaterials have been used to enable drug delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells. Different nanoparticles have been developed using different polymers with or without surface modification to target tumor cells both passively and/or actively. Polylactide-co-glycolide (PLGA), a biodegradable polyester approved for human use, has been used extensively. Here we report on recent developments concerning PLGA nanoparticles prepared for cancer treatment. We review the methods used for the preparation and characterization of PLGA nanoparticles and their applications in the delivery of a number of active agents. Increasing experience in the field of preparation, characterization, and in vivo application of PLGA nanoparticles has provided the necessary momentum for promising future use of these agents in cancer treatment, with higher efficacy and fewer side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Nanoparticle and targeted systems for cancer therapy
Brannon-Peppas, L., & Blanchette, J. O. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.014 · Cited by 2,334
Nanocapsule formation by interfacial polymer deposition following solvent displacement
Fessi, H., Puisieux, F., Devissaguet, J. P., Ammoury, N., & Benita, S. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90281-0 · Cited by 2,288
Jain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
Girois, S., Audouin, L., Jacques Verdu, C., Delprat, P., & Marot, G. (1996) · Cited by 2,213
Cited by
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Elmowafy, E. M., Tiboni, M., & Soliman, M. E. (2019) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-019-00439-x · Cited by 621
PLGA-Based Nanoparticles in Cancer Treatment
Rezvantalab, S., Drude, N. I., Moraveji, M. K., Güvener, N., Koons, E. K., Shi, Y., Lammers, T., & Kiessling, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01260 · Cited by 607
Vitamin E TPGS as a molecular biomaterial for drug delivery
Zhang, Z., Tan, S., & Feng, S.-S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.046 · Cited by 586
Double emulsion solvent evaporation techniques used for drug encapsulation
Iqbal, M., Zafar, N., Fessi, H., & Elaissari, A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.10.057 · Cited by 560
PLGA-Based Nanoparticles as Cancer Drug Delivery Systems
Tabatabaei Mirakabad, F. S., Nejati-Koshki, K., Akbarzadeh, A., Yamchi, M. R., Milani, M., Zarghami, N., Zeighamian, V., Rahimzadeh, A., Alimohammadi, S., Hanifehpour, Y., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.2.517 · Cited by 542
Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy
Raj, S., Khurana, S., Choudhari, R., Kesari, K. K., Kamal, M. A., Garg, N., Ruokolainen, J., Das, B. C., & Kumar, D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.002 · Cited by 425
Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics
Ding, D., & Zhu, Q. (2018) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.12.036 · Cited by 386
Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications
Martins, C., Sousa, F., Araújo, F., & Sarmento, B. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701035 · Cited by 362
PLGA-Based Composites for Various Biomedical Applications
Rocha, C. V., Gonçalves, V., da Silva, M. C., Bañobre-López, M., & Gallo, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042034 · Cited by 350
Oxidative stress in apoptosis and cancer: an update
Matés, J. M., Segura, J. A., Alonso, F. J., & Márquez, J. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0906-3 · Cited by 341
Customizing poly(lactic-co-glycolic acid) particles for biomedical applications
Swider, E., Koshkina, O., Tel, J., Cruz, L. J., de Vries, I. J. M., & Srinivas, M. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.04.006 · Cited by 328
PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up
Operti, M. C., Bernhardt, A., Grimm, S., Engel, A., Figdor, C. G., & Tagit, O. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120807 · Cited by 302
Rafiei, P., & Haddadi, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s121881 · Cited by 284
Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases
Deng, Y., Zhang, X., Shen, H., He, Q., Wu, Z., Liao, W., & Yuan, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00489 · Cited by 259
Recent developments in the use of nanoparticles for treatment of biofilms
Han, C., Romero, N., Fischer, S., Dookran, J., Berger, A., & Doiron, A. L. (2017) · Nanotechnology Reviews · doi:10.1515/ntrev-2016-0054 · Cited by 114
Li, H., Liu, B., Ao, H., Fu, J., Wang, Y., Feng, Y., Guo, Y., & Wang, X. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0565-0 · Cited by 28
History, introduction, and properties of PLGA as a drug delivery carrier
Yurtdaş Kırımlıoğlu, G. (2023) · Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug Delivery · doi:10.1016/b978-0-323-91215-0.00001-7 · Cited by 9
Metadata
- Authors
- Dinarvand, R., Sepehri, N., Manouchehri, Rouhani, & Atyabi, F.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2011-04
- Volume
- 6
- Pages
- 877
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W1977718036
- Cited by
- 453
- References
- 158
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.